April 12, 2018 / 6:07 AM / in 7 months

BRIEF-Integragen Presents Positive Data From Liquid Biopsy Studies Of miRNAs

April 12 (Reuters) - INTEGRAGEN SA:

* INTEGRAGEN PRESENTS POSITIVE DATA FROM LIQUID BIOPSY STUDIES OF COMPANY’S PROPRIETARY MIRNAS DURING 2018 EUROPEAN LUNG CANCER CONFERENCE

* CO’S PROPRIETARY MIRNA BIOMARKERS PREDICT EGFR TYROSINE KINASE INHIBITOR (EGFR-TKI) TREATMENT RESPONSE

* MIRNA BIOMARKERS IDENTIFY DRUG RESISTANCE EMERGENCE IN LUNG ADVANCED SQUAMOUS CELL CARCINOMA PATIENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below